Trends Analysis of Sexually Transmitted Infections Before and After Human Immunodeficiency Virus Pre-exposure Prophylaxis in the United States 2001-2022

美国2001-2022年人类免疫缺陷病毒暴露前预防前后性传播感染趋势分析

阅读:2

Abstract

BACKGROUND: The correlation between human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) usage and sexually transmitted infections (STIs) remains equivocal. Limited studies have investigated national STI trends after introducing PrEP. We aimed to examine STI incidence before and after PrEP introduction and explore correlations with PrEP use in the United States. METHODS: PrEP usage data (2012-2022) were obtained from AIDSVu, and STI data (2001-2022) from the Centers for Disease Control and Prevention's STI Statistics Archive. We used the coefficient of determination to estimate variance in STI rates explained by PrEP usage. We used cross-correlation to identify lagged correlations and segmented linear regression to examine STI trends by demographics before and after PrEP initiation. RESULTS: Syphilis rates increased by 0.2/100 000 people annually before 2012 and by 1.4/100 000 persons after PrEP introduction. Gonorrhea rates dropped by 2.9/100 000 people before 2012 but rose by 14/100 000 afterward. The slope for chlamydia dropped from 20.9 to 6.6. The coefficients of determination for syphilis, gonorrhea, and chlamydia attributable to PrEP usage were 0.98, 0.88, and 0.2, respectively. Lagged correlations were significant for chlamydia, but not for syphilis and gonorrhea. Overall, STI rates were more strongly correlated with PrEP usage among males than females. CONCLUSIONS: We found significant changes in the rate of incident STIs from 2012 to 2022 and a high correlation between PrEP usage and reported cases of syphilis and gonorrhea. Given the role of PrEP in comprehensive HIV prevention in the United States, its impact on rates of STI infection should be further studied.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。